Paul Bendheim, M.D.
Chairman
Dr. Bendheim obtained his B.A. from Pomona College, Claremont, and his M.D. degree from the University of Arizona College of Medicine. He held various positions at the Laboratory of Transmissible Neurodegenerative Diseases and the Geriatric Neurology Clinic. Dr. Bendheim was a Visiting Professor in the Department of Neurobiology at the Weizmann Institute of Science, Medical Director of the Copaxone Division at Teva Pharmaceuticals, and Executive Vice President & Chief Medical Officer of Mindset Biopharmaceuticals. Dr. Bendheim is the Medical Director of Development and a research neurologist of the AD Institute of the Banner Good Samaritan Medical Center, in Phoenix, Arizona and is the Founder and Chairman of BrainSavers, a company that has developed a program to maintain and improve brain function as individuals age.

Steven H. Ferris, Ph.D.

Prof. Ferris obtained his B.A. in Psychology at Rensselaer Polytechnic Institute, his M.A. in Psychology at Queens College and his Ph.D. in Experimental Psychology at the City University of NY. He has held several academic appointments in the department of Psychiatry at the NYU School of Medicine, where he is the Gerald J. & Dorothy R. Friedman Prof. of the NYU AD Center. He is the Executive Director of the Aging and Dementia Research Center and the Director of the National Institutes on Aging AD Center at the NYU School of Medicine. He is currently directing a national, NIH consortium study designed to improve the efficiency of primary prevention trials for AD.

Douglas R. Galasko, M,D.

Prof. Galasko is a member of the Department of Neurosciences at the School of Medicine, Univeristy of California,SD. His specific areas of investigation include biological markers and genetic risk factors for Alzheimer's Disease (AD), heterogeneity in AD, and subtypes and variants. He is an Investigator at the UCSD Shiley-Marcos Alzheimer's Disease Research Center and developed the assessment instrument for activities of daily living (ADL) as part of an Alzheimer's Disease Cooperative Study (ADCS) instrument development protocol.

Eric Reiman, M.D.

Dr. Reiman attended medical school at Duke University and did his residency at Duke and Washington University. He is the Director, Alzheimer's Disease Research Program & Scientific Director, PET Center, Banner Good Samaritan Medical Center; Clinical Director, Neurogenomics Program, Translational Genomics Research Institute (TGen) and Professor and Associate Head for Research and Development (Phoenix Campus), Department of Psychiatry, The University of Arizona.

Thomas M. Wisniewski, M.D.

Dr. Wisniewski obtained his M.D. from Kings College School of Medicine in the UK. He did his Neurology and Neuropathology Residencies at New York University and Columbia-Presbyterian, respectively. Dr. Wisniewski is Professor of Neurology, Pathology and Psychiatry at New York University Medical Center and is a board certified Neurologist and Neuropathologist, he is also the Director of the Memory and Dementia Disorders Center and the Director of the Neuropathology Core of the NYU Alzheimer's Disease Center. Dr. Wisniewski has an active research laboratory focusing on neurodegenerative disorders, in particular the mechanisms which drive amyloid deposition in Alzheimer's and prion related diseases. This work has lead to over 150 peer-reviewed publications.